Radisys Introduces White Box Combo PON Optical Line Terminals for Next-Gen FTTX Networks
13.7.2021 15:00:00 EEST | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today introduced the Radisys Combo PON Optical Line Terminal (OLT) as part of the Radisys Connect Open Broadband portfolio for broadband service providers. The complete family of Radisys OLTs includes 16 and 32-port versions—a variant of which is the Radisys white box Combo PON OLT that supports both G-PON (2.488 Gbps downstream / 1.244 Gbps upstream) and XGS-PON (10 Gbps symmetrical) within the same PON port of the OLT. The white box OLTs are based on the VOLTHA/SEBA reference architecture and are field-hardened and scaled for commercial deployments today.
News Highlights
- A growing number of global service providers are moving forward with XGS-PON as their next-generation PON technology of choice. Analyst firm Dell-Oro Group predicts XGS-PON will be the favored PON technology for the future.
- Radisys’ Combo PON OLT allows broadband providers to take advantage of pervasive G-PON technology while giving them a flexible upgrade path to scale up and rollout XGS-PON deployments without costly rip and replace.
-
Radisys’ Combo PON OLT is an open, flexible, highly scalable telco-grade white box designed to address service providers’ key needs.
- Full PON port flexibility enables G-PON, XGS-PON or Combo PON (G-PON and XGS-PON) on any port on the same platform.
- Open architecture delivers datacenter-driven cost efficiencies and high port densities, making it suitable for residential, cloud and enterprise services to simplify deployments and reduce operating expenses.
- Compatibility with any ONF VOLTHA-based software, including Radisys’ Connect Broadband Access Controller (CBAC) software, allows service providers to scale hardware up or down while the management software and all other Connect Open Broadband components remain intact.
- Flexibility to deploy virtualized functions either in a distributed fashion running within the OLT CPU, or as a centralized function hosted on an external server or a public or private cloud.
- Radisys’ Combo PON OLTs are part of the Connect Open Broadband product suite, which includes open and disaggregated software, hardware and management.
- The complete family of Radisys OLTs also includes the 16 and 32-port OLTs. The Radisys 32 port G-PON OLT (RLT-3200G) was recently certified for VOLTHA v2.8 through Open Networking Foundation’s Continuous Certification Program.
“Radisys’ Combo PON OLTs give broadband providers an optimal economic advantage with the flexibility to use both G-PON and XGS-PON in their networks and through a reduction in space and power consumption,” said Harris Razak, senior vice president of Broadband Access, Radisys. “All products in the Connect Open Broadband portfolio utilize the same management system and controlling software, allowing our provider customers to choose the features and capacity they want while keeping other network elements the same, lowering their total cost of ownership and optimizing their Capex and Opex.”
“We are pleased that Radisys’ 32-port G-PON OLT has been named a certified VOLTHA product within the ONF Continuous Certification Program. This certification, along with the introduction of the Radisys Combo PON OLT with support for VOLTHA/SEBA, offers broadband service providers with greater solution choices for their FTTX deployments,” said Guru Parulkar, ONF Executive Director. “As an ONF Partner Member, Radisys has been instrumental in the development of ONF open reference designs as well as the commercialization of ONF-based solutions. The Continuous Certification Program ensures that service providers can easily identify certified products for specific ONF projects within a vibrant ecosystem of vendors delivering and deploying ONF open source platforms.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005445/en/
Contact information
Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
